RetroSense Therapuetics Logowhite spacerGo to about RetroSenseGo to Investors and Partners pageGo to Product DevelopmentGo to Therapeutics AreasGo to Frequently Asked QuestionsGo to Contact Page
left image bandRight Image band
photoRetroSense Therapeutics develops game-changing gene therapy solutions to restore partial sight for certain eye diseases.
Board of Directors

Sean Ainsworth
Chairman of the Board


Sean Ainsworth has twenty years of experience in pharmaceuticals and biotechnology. He has had deep involvement in the launch of two earlier startup companies, Compendia Bioscience, Inc. and GeneVivo, LLC where he assisted in developing business models, licensing technologies, building management teams, securing capital and first customers. Compendia BioScience was acquired by Life Technologies in October, 2012.

His experience also includes research at Medical Biology Institute (now Avanir Pharmaceuticals developers of Abreva, the leading cold sore medication) in San Diego, intellectual property at Koyama and Associates in Tokyo, international corporate development consulting at The Mattson Jack Group in St. Louis, MO.

In 2004 Mr. Ainsworth launched Ainsworth BioConsulting to provide licensing, strategic planning, and business planning services to the life science and entrepreneurial community. Mr. Ainsworth’s clients included large pharma, small biotechs, universities, CROs, and venture investment funds. He has worked with clients at all stages of development.

Mr. Ainsworth holds a BS in Microbiology from University of California, San Diego and an MBA in strategy and finance from Washington University in St. Louis.


(return to top of page)

Cam Gallagher

Mr. Gallagher currently serves as Managing Director of Nerveda, LLC, a life science seed fund he founded in June 2009. Previously, from September 2007 until June 2009, Mr. Gallagher served as President and Chief Executive Officer of Nerveda, a privately held specialty pharmaceutical company.

Since October 2008, Mr. Gallagher has served as Chairman of the Board of Directors of DioGenix, a privately held molecular diagnostic company and he has served on the Board of Directors of Sorrento Therapeutics since September 2012. From December 2004 through June 2007, Mr. Gallagher served in various senior marketing positions at Verus Pharmaceuticals, a privately held specialty pharmaceutical company. Mr. Gallagher holds an M.B.A. from the University of San Diego and a B.Sc. in Business Administration from the Ohio University.


(return to top of page)

Ken Kousky

An experienced chief executive and financial economist, Ken is a veteran of the information technology industry. Ken has successfully started three companies and played instrumental roles in two turnarounds and two IPO’s. In 1988, Ken founded an IT services company, Wave Technologies, and within six years, he guided his vision from home through an IPO to a successful public company. An active investor in start-ups, Ken is a founding member and Executive Director of the BlueWater Angels Investment Network. In addition, Ken serves on the Public Policy Committee of the Angel Capital Association.

(return to top of page)

Alexey Konov, PhD

Alexey Konov. Graduate from Moscow State University (1989) and Ph.D from University Louis Pasteur (1998); professional in life sciences start-up venture financing and management. After 10 years in academic science and 15 years in the corporate world Alexey, in 2006, co-founded the first Russian biotech venture fund. He served as its Investment Director and as Chairman of the Board in several fund portfolio companies in Russia, EU and US. In the end of 2012 he founded independent RBV Capital which made its first closing in 2014 by a prominent industrial LP, leveraged by the top local fund-of-funds. RBV Capital started investing in 2015.

(return to top of page)

Terry Cross

After graduating from Wayne State University in 1966 with an MBA in Finance, Terry co-founded CP Systems Company and sold it in 1972 to a NYSE listed company for more than $10.0 million.

From 1972 until 1998, Terry worked for Kidder, Peabody and its successor, PaineWebber Inc. in Detroit, New York City and Silicon Valley, covering companies and venture capitalists. In 1998 he left Paine Webber and co-founded Sonoma Photonics where he led a $14.0 million venture financing and successful launch of the company. He served as Chairman and CEO until returning to Michigan in 2002. Sonoma Photonics was sold to Lockheed-Martin in 2008 for a significant return.

Terry has served as director of 12 companies as well as Chairman of 3 companies. Over forty years he has invested in 44 venture deals including the following that became publicly traded: Novell, DSC Communications, Napster, PayPal, Inkotomi, Warehouse Club and he was an angel round investor in Google.

Since returning to Michigan, he founded Windward Associates, a capital formation advisory, to assist young companies in connecting and growing in the entrepreneurial ecosystem in Michigan. He is a founding member of The Michigan Venture Capital Association and has served, and continues to serve on many economic development committees and judging panels.

(return to top of page)

Anthony Sun, MD

Tony Sun, a biotechnology industry consultant, has been involved in numerous life science companies activities from company formation to fund raising to capital market exits to acquisitions. He has spent the last 13 years on the investment side of the business, first at Perseus-Soros BioPharmaceutical Fund and then at Aisling Capital where he served as Partner. Previously, Tony was an Adjunct Instructor of Medicine at the Hospital of the University of Pennsylvania.

Tony received his MD from Temple University School of Medicine with A.O.A. honors. He received his MBA from The Wharton School at the University of Pennsylvania, and his BS in Electrical Engineering from Cornell University. In addition, he has been Board Certified in Internal Medicine.

(return to top of page)